Pneumococcal conjugate vaccination in persons with HIV: The effect of highly active antiretroviral therapy

AIDS

Volumn 24, Issue 9, 2010, Pages 1315-1322

  Søgaard, Ole S ^a   Schønheyder, Henrik C ^a   Bukh, Anne R ^a   Harboe, Zitta B ^b   Rasmussen, Thomas A ^a   Østergaard, Lars ^a   Lohse, Nicolai ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

Highly active antiretroviral therapy; HIV; Immunogenicity; Immunologic adjuvants; Pneumococcal vaccines

Indexed keywords

AGATOLIMOD; ANTIRETROVIRUS AGENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; PNEUMOCOCCUS VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODY FORMATION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DENMARK; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; PNEUMOCOCCAL VACCINES; RNA, VIRAL; TOLL-LIKE RECEPTOR 9; VACCINES, CONJUGATE;

EID: 77952932853     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328339fe0b     Document Type: Article

References (40)

1. Kohli R, Lo Y, Homel P, Flanigan TP, Gardner LI, Howard AA, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006; 43:90-98.
2. Sogaard OS, Lohse N, Gerstoft J, Kronborg G, Ostergaard L, Pedersen C, et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008; 47:1345-1353.
3. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococ-cal disease in San Francisco County, California. Ann Intern Med 2000; 132:182-190.
4. Redd SC, Rutherford GW III, Sande MA, Lifson AR, Hadley WK, Facklam RR, Spika JS. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990; 162:1012-1017.
5. Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS 2006; 20:437-444.
6. Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533-1540.
7. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207; quiz CE201-CE204.
8. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-2111.
9. Rodriguez-Barradas MC, Goulet J, Brown S, Goetz MD, Rimland D, Simberkoff MS, et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5 Site Study. Clin Infect Dis 2008; 46:1093-1100.
10. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE; Adult, Adolescent Spectrum of HIVDP. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32:794-800.
11. Teshale EH, Hanson D, Flannery B, Phares C, Wolfe M, SchuchatA,SullivanP. Effectiveness of23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998-2003. Vaccine 2008; 26:5830-5834.
12. Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, et al. Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults. Clin Diag Lab Immunol 2004; 11:137-141.
13. Madhi SA, Klugman KP, Kuwanda L, Cutland C, Kayhty H, Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis 2009; 199:1168-1176.
14. Scriba TJ, Zhang HT, Brown HL, Oxenius A, Tamm N, Fidler S, et al. HIV-1-specific CD4R T lymphocyte turnover and activation increase upon viral rebound. J Clin Invest 2005; 115:443-450.
15. Titanji K, De Milito A, Cagigi A, Thorstensson R, Grutzmeier S, Atlas A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006; 108:1580-1587.
16. D'Orsogna LJ, Krueger RG, McKinnon EJ, French MA. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS 2007; 21:1747-1752.
17. Berberian L, Goodglick L, Kipps TJ, Braun J. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 1993; 261:1588-1591.
18. H3 expression in peripheral B cells from human immunodeficiency virus (HIV)-uninfected but not HIV-in-fected persons. J Infect Dis 2000; 181:1313-1321.
19. Mogensen TH, Paludan SR, Kilian M, Ostergaard L. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Tolllike receptors 2, 4, and 9 in species-specific patterns. J Leukoc Biol 2006; 80:267-277.
20. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-484.
21. Lester RT, Yao XD, Ball TB, McKinnon LR, Kaul R, Wachihi C, et al. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS 2008; 22:685-694.
22. Nowroozalizadeh S, Mansson F, da Silva Z, Repits J, Dabo B, Pereira C, et al. Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections. Cytokine 2009; 46:325-331.
23. Verthelyi D, Wang VW, Lifson JD, Klinman DM. CpG oligo-deoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS 2004; 18:1003-1008.
24. Søgaard OS, Lohse N, Harboe ZB, Offersen R, Bukh AR, Davis HL, et al. Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV-infected Adults with a TLR9 agonist-adjuvant. A Randomized Trial. Clin Infect Dis 2010; in press.
25. Konradsen HB, Sorensen UB, Henrichsen J. A modified enzyme-linked immunosorbent assay for measuring type-specific antipneumococcal capsular polysaccharide antibodies. J Immunol Methods 1993; 164:13-20.
26. Skovsted IC, Kerrn MB, Sonne-Hansen J, Sauer LE, Nielsen AK, Konradsen HB, et al. Purification and structure characterization of the active component in the pneumococcal 22F poly-saccharide capsule used for adsorption in pneumococcal enzyme-linked immunosorbent assays. Vaccine 2007; 25: 6490-6500.
27. Martinez JE, Clutterbuck EA, Li H, Romero-Steiner S, Carlone GM. Evaluation of multiplex flow cytometric opsonophagocy-tic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae. Clin Vaccine Immunol 2006; 13:459-466
28. Pneumococcal conjugate vaccine for childhood immunization: WHO position paper. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations. Weekly Epidemiological Record/Health Section of the Secretariat of the League of Nations; 2007; 82:93-104.
29. Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009; 27:4731-4738.
30. Crane HM, Dhanireddy S, Kim HN, Ramers C, Dellit TH, Kitahata MM, Harrington RD. Optimal timing of routine vaccination in HIV-infected persons. Curr HIV/AIDS Rep 2009; 6:93-99.
31. Nielsen H, Kvinesdal B, Benfield TL, Lundgren JD, Konradsen HB. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis 1998; 30:597-601.
32. Lesprit P, Pedrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21:2425-2434.
33. Gordin FM, Roediger MP, Girard PM, Lundgren JD, Miro JM, Palfreeman A, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med 2008; 178:630-636.
34. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hy-poresponsiveness an issue? Lancet Infect Dis 2007; 7:597-606.
35. Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, et al. The immunogenicity of 7-valent pneumo-coccal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009; 49:1318-1325.
36. Vernacchio L, Romero-Steiner S, Martinez JE, MacDonald K, Barnard S, Pilishvili T, et al. Comparison of an opsonophago-cytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J Infect Dis 2000; 181:1162-1166.
37. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 2005; 192:1988-1995.
38. Yu X, Gray B, Chang S, Ward JI, Edwards KM, Nahm MH. Immunity to cross-reactive serotypes induced by pneumococ-cal conjugate vaccines in infants. J Infect Dis 1999; 180:1569-1576.
39. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpatho-genic AIDS virus infections. Nat Med 2008; 14:1077-1087.
40. Albiger B, Dahlberg S, Sandgren A, Wartha F, Beiter K, Katsuragi H, et al. Toll-like receptor 9 acts at an early stage in host defence against pneumococcal infection. Cell Microbiol 2007; 9:633-644.